Group 1 - The company, Yaoshi Bang (09885.HK), announced a share buyback on November 6, spending HKD 3.235 million to repurchase 400,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括 ...

本公司董事會（「董事會」）注 意 到，本 公 司 股 份（「股 份」）之價格及成交量近期出現 異 常 變 動。經 就 本 公 司 作 出 在 有 關 情 況 下 屬 合 理 的 一 切 查 詢 後，董 事 會 確 認， 概不知悉(i)導 致 股 份 出 現 該 等 股 價 及 成 交 量 異 常 變 動 之 任 何 原 因；或(ii)任 何 須 予 公 佈 以 避 免 股 份 出 現 虛 假 市 場 之 資 料；或(iii)根據上市規則第13.09(2)條 及 證券及期貨條例（香 港 法 例 第571章）第XIVA部 須 予 披 露 之 任 何 內 幕 消 息。 董 事 會 同 時 確 認，本 公 司 業 務 運 作 維 持 正 常，截 至 本 公 告 日 期 之 業 務 經 營 及 財 務 狀 況 並 無 重 大 變 動。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 股價及成交量的異常變動 及 股份回購 及 執行董事增持股份 此公告乃藥師幫股份有限公司（「本公司」）自願向本公司股東（「股 東」）及本公司 潛 在 ...

Group 1 - The core point of the article is that Chen Fei increased his stake in Yaoshibang (09885) by purchasing 200,000 shares at approximately HKD 7.69 per share, totaling HKD 1.538 million [1] - After the purchase, Chen Fei's total shareholding in Yaoshibang reached 8.5 million shares, representing a 1.25% ownership stake [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | ...

Core Insights - The article highlights the challenges faced by grassroots medical institutions in China due to a surge in respiratory infectious diseases, particularly influenza, amid a strong cold wave [1][2] - The digital pharmaceutical platform, Yaoshi Bang, is actively addressing the medication supply needs at the grassroots level through its digital supply chain system [1] Group 1: Company Performance - Yaoshi Bang has established deep strategic partnerships with several domestic pharmaceutical companies to ensure stable supply of core medications, including a full range of influenza treatment drugs like Oseltamivir [1] - The platform has reported a 36% year-on-year increase in overall sales of influenza-related medications since October 2025, with demand for Oseltamivir granules and capsules surging by 120% [1] - The company's proprietary brand "Leyaoshi" for cold medications has also seen a sales increase of over 135% year-on-year due to its cost-effectiveness [1] Group 2: Industry Context - The National Influenza Center's latest monitoring indicates an upward trend in influenza activity in southern provinces of China, with a notable increase in the positive rate of H3N2 influenza virus tests in certain areas [1] - The combination of high influenza incidence and cold weather has intensified the need for timely replenishment and precise allocation of grassroots medical resources, which is critical for effective disease control [2] - Yaoshi Bang's integration of upstream pharmaceutical resources, intelligent scheduling, and downstream rapid testing services enhances its capability to provide comprehensive support for medication supply and diagnosis during the flu season [2]

Core Insights - The article highlights the challenges faced by grassroots medical institutions in China due to a strong cold wave and a surge in respiratory infectious diseases, particularly influenza [1][2] - The digital pharmaceutical platform, Yaoshi Bang, is actively addressing the medication supply and treatment service demands in grassroots healthcare through its digital supply chain system [1] Group 1: Company Performance - Yaoshi Bang has established deep strategic partnerships with several domestic pharmaceutical companies to ensure stable supply of core medications, including a full range of influenza treatment drugs like Oseltamivir [1] - The platform reported a significant increase in sales of influenza-related medications, with an overall sales growth of 36% year-on-year since October 2025, and a 120% increase in sales of Oseltamivir products [1] - The company's own brand, "Leyaoshi," saw a sales growth exceeding 135% year-on-year due to its cost-effective offerings [1] Group 2: Service Innovations - Yaoshi Bang has introduced the "Spectrum Cabin" smart healthcare solution to empower the diagnostic end, alleviating pressure on grassroots healthcare during the flu season [2] - The core product, the Immunity Small Box, supports rapid testing for influenza A and B, with a month-on-month increase in testing numbers exceeding 60% in October [2] - The integration of upstream pharmaceutical resources, intelligent scheduling, and downstream smart testing services enhances Yaoshi Bang's ability to provide comprehensive support for medication supply and treatment during the flu season [2]

Summary of Key Points Core Viewpoint - On October 27, 34 Hong Kong-listed companies conducted share buybacks, totaling 15.35 million shares and an aggregate amount of HKD 76.77 million, indicating a trend of companies returning capital to shareholders through buybacks [1]. Group 1: Buyback Details - China Feihe repurchased 5.89 million shares for HKD 24.07 million, with a highest price of HKD 4.09 and a lowest price of HKD 4.08, accumulating HKD 57.07 million in buybacks for the year [1][2]. - Gushengtang repurchased 244,400 shares for HKD 7.19 million, with a highest price of HKD 29.66 and a lowest price of HKD 29.22, totaling HKD 256.39 million in buybacks for the year [1][2]. - Mengniu Dairy repurchased 400,000 shares for HKD 5.77 million, with a highest price of HKD 14.46 and a lowest price of HKD 14.38, accumulating HKD 480 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 27 was by China Feihe at HKD 24.07 million, followed by Gushengtang at HKD 7.19 million, and Mengniu Dairy among the top [1][2]. - In terms of share quantity, China Feihe led with 5.89 million shares repurchased, followed by Chenxun Technology and Lianyi Technology-W with 1.45 million and 1.16 million shares, respectively [1][2]. Group 3: Additional Buyback Information - The buyback by Puleshi Group Holdings was noted as its first for the year, while Mengniu Dairy has conducted multiple buybacks totaling HKD 480 million [2]. - A detailed table of buybacks on October 27 includes various companies, their respective buyback shares, amounts, highest and lowest prices, and cumulative buyback amounts for the year [2][3].

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on October 27, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - China Feihe (06186) repurchased 5.886 million shares for a total of 24.0721 million yuan, representing 0.152% of its total share capital with a year-to-date total of 13.771 million shares repurchased [1][2] - Guosheng Tang (02273) repurchased 244,400 shares for 7.1899 million yuan, with a year-to-date total of 5.5026 million shares, accounting for 2.322% of its total share capital [2] - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7710 million yuan, with a year-to-date total of 21.716 million shares, representing 0.555% of its total share capital [2] Group 2: Other Notable Buybacks - Lianlian Digital (02598) repurchased 711,000 shares for 5.7458 million yuan, with a year-to-date total of 2.5925 million shares, accounting for 0.620% of its total share capital [2] - Zhongxu Future (09890) repurchased 345,200 shares for 5.0690 million yuan, with a year-to-date total of 647,400 shares, representing 1.210% of its total share capital [2] - Kangchen Pharmaceutical (01681) repurchased 100,000 shares for 1.5400 million yuan, with a year-to-date total of 740,600 shares, accounting for 8.700% of its total share capital [2][3]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 FF305 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年10月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份 ...